8-K: Immunocore Reports Strong Q1 2024 Revenue Growth and Pipeline Progress

Immunocore announced a 36% increase in KIMMTRAK revenue year-over-year for Q1 2024, alongside advancements in its clinical pipeline.

Summary

• Immunocore reported a net product revenue of $70.3 million from KIMMTRAK sales in Q1 2024, a 36% increase compared to Q1 2023.
• The company's revenue was primarily driven by $50.0 million in the United States, $19.0 million in Europe, and $1.4 million in international regions.
• Research and development expenses increased to $57.5 million, up from $36.6 million in the same period last year, due to the advancement of the PRAME programs.
• Selling, general, and administrative expenses rose to $39.3 million, compared to $32.6 million in Q1 2023, due to increased business support functions.
• The net loss for the quarter was $24.4 million, compared to a net loss of $19.4 million in Q1 2023.
• The basic and diluted loss per share was $0.49, compared to $0.40 for the first quarter of 2023.
• Cash and cash equivalents stood at $832.8 million as of March 31, 2024, which includes $390.2 million from a convertible notes offering in February 2024.
• The company plans to use $50 million from the convertible notes to repay an existing loan by the end of 2024.
• KIMMTRAK is now approved in 38 countries and launched in 17, with 7 new launches since January 2024.
• The company is progressing its PRAME franchise, with the first patient randomization in the PRISM-MEL-301 trial expected in Q2 2024.
• The company is also advancing its ImmTAV and ImmTAAI platforms for infectious and autoimmune diseases, respectively.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, a robust cash position, and significant clinical pipeline advancements. The company is executing well on its strategy, and the market is likely to react favorably.

Positives

• KIMMTRAK sales are growing strongly, with a 36% increase in revenue compared to the same quarter last year.
• The company has successfully expanded the global reach of KIMMTRAK with 7 new country launches.
• Immunocore has a strong cash position of $832.8 million, providing financial stability for ongoing research and development.
• The company is making good progress with its clinical pipeline, including the advancement of brenetafusp and other candidates.
• The TEBE-AM trial is recruiting ahead of schedule, indicating strong interest and progress in clinical trials.
• The company is expanding its platform into autoimmune diseases with two new, first-in-class bispecific candidates.

Negatives

• The company reported a net loss of $24.4 million for the quarter, an increase compared to the $19.4 million loss in the same period last year.
• Research and development expenses have increased significantly, which may impact profitability in the short term.
• Selling, general, and administrative expenses have also increased, reflecting the growing scale of the company's operations.

Risks

• The company's financial performance is subject to the risks associated with clinical trials, including delays and unexpected results.
• The company faces competition in the market for cancer and other therapies.
• The company's ability to obtain and maintain regulatory approvals for its products is subject to regulatory risks.
• The company's future success depends on its ability to successfully commercialize its products and expand into new markets.
• The company's financial performance is subject to macroeconomic conditions and global geopolitical tensions.

Future Outlook

The company anticipates continued growth in KIMMTRAK sales, further expansion into new markets, and advancement of its clinical pipeline, including the start of the first registrational trial for brenetafusp and the exploration of new TCR treatments across oncology, infectious diseases, and autoimmune diseases. The company also expects to present additional clinical data throughout 2024.

Management Comments

• With our differentiated pipeline, we continue to work with a sense of urgency to bring KIMMTRAK to more patients; start the first registrational trial for brenetafusp, our PRAME ImmTAC therapy; and explore innovative new TCR treatments across oncology, infectious diseases, and autoimmune diseases, said Bahija Jallal, Chief Executive Officer of Immunocore.
• We continue to gain insights into our ImmTAC platform, drawing on data from over 1,000 patients treated in our clinical programs. I am particularly pleased that the brenetafusp melanoma data has been selected for an oral presentation at ASCO, said Mohammed Dar, Head of Clinical Development and Chief Medical Officer.

Industry Context

This announcement reflects the ongoing trend in the biotechnology industry towards developing novel immunotherapies for cancer and other diseases. Immunocore's focus on TCR-based therapies positions it as a key player in this space, with its KIMMTRAK product demonstrating commercial success and its pipeline showing promise for future growth. The collaboration with Bristol Myers Squibb also highlights the industry's move towards combination therapies to improve patient outcomes.

Comparison to Industry Standards

• Immunocore's 36% year-over-year revenue growth for KIMMTRAK is strong compared to other commercial-stage biotech companies, particularly in the rare cancer space.
• The company's cash position of $832.8 million is robust, providing a solid foundation for continued investment in research and development, which is comparable to other companies with similar market caps.
• The advancement of multiple clinical programs across different therapeutic areas, including oncology, infectious diseases, and autoimmune diseases, is a positive sign of a diversified pipeline, which is a common strategy among leading biotech firms.
• The selection of brenetafusp data for oral presentation at ASCO is a significant achievement, indicating the potential of the company's PRAME franchise, which is similar to other companies with novel therapeutic platforms.
• The collaboration with Bristol Myers Squibb is a strategic move, aligning with the industry trend of partnerships to accelerate drug development and commercialization, similar to other biotech companies.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and pipeline progress positively.
• Employees may benefit from the company's growth and expansion.
• Patients may benefit from the development of new therapies for cancer and other diseases.
• Customers will have increased access to KIMMTRAK in more countries.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's strong cash position favorably.

Next Steps

• The company plans to continue global expansion of KIMMTRAK.
• The company expects to start the first registrational trial for brenetafusp in Q2 2024.
• The company will present additional clinical data throughout 2024.
• The company will submit IND or CTA applications for IMC-P115C and IMC-T119C.
• The company will start a Phase 1 clinical trial for IMC-R117C in the second half of 2024.
• The company will present MAD data for IMC-M113V in the second half of 2024.

Key Dates

Keywords

KIMMTRAK, Immunocore, brenetafusp, uveal melanoma, cutaneous melanoma, ImmTAC, ImmTAV, ImmTAAI, clinical trials, cancer, immunotherapy, PRAME, HIV, Hepatitis B, autoimmune diseases